On Monday, Shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM), gained 8.59% to $2.15.
Actinium Pharmaceuticals successfully accomplished foundational phases of development of an antibody construct labeled with actinium-225 using the Company’s novel proprietary APIT (Alpha Particle Immunotherapy Technology) platform. This new pipeline entry further validates the robustness of Actinium’s platform technology. The labeled antibody has the potential to be broadly used in the field of hematology/oncology. Quality control testing of the new construct has confirmed that the product meets or exceeds all specifications related to biological integrity and properties of the labeled antibody. Early animal work has confirmed the biological properties of this new antibody drug conjugate (ADC).
Based on the successful outcome of this first phase in this new development program, collaborating parties are ongoing preclinical development of the product leading to clinical trials. The Company is further evaluating biological effectiveness in appropriate animal models and also validating the clinical and market opportunity applicable to this product candidate. Assuming that the clinical and market potential of this antibody construct are confirmed, the Company anticipates to unveil the development plan and timing for the latest pipeline entry in the fourth quarter of 2015.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products comprise Actimab-A, an antibody-drug construct, which comprises monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML).
Shares of Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), declined -39.05% to $13.44, during its last trading session.
Karyopharm Therapeutics stated financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
“Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was presented during the quarter, counting single agent anti-tumor activity and durable disease control in patients with recurrent glioblastoma, advanced sarcomas, ovarian and endometrial cancers. We also presented survival data in patients with relapsed/refractory diffuse large B-cell lymphoma treated with selinexor, together with combination data of selinexor with chemotherapy in patients with heavily pretreated acute myeloid leukemia,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “In addition, we continue to execute against the selinexor clinical development plan with the initiation of a Phase 2 study in patients with quad-refractory multiple myeloma and make steady progress enrolling patients in our other on-going later phase clinical trials in acute myeloid leukemia, diffuse large B cell lymphoma and Richter’s transformation. Furthermore, we made some important changes to certain trials based on our growing experience with selinexor. Finally, we recently met with FDA and now have a path forward for a phase 2/3 study in liposarcoma. In the second half of 2016, we look forward to reporting preliminary top-line data from our later phase clinical trials in AML, DLBCL and Richter’s transformation, in addition to data from the first 80 patients in our later phase clinical trial in multiple myeloma in the middle of 2016.”
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
